Logo
x

Search

Subscribe Now

Alzheimer disease

GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease

GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease

  • April 23, 2024
Genentech's Gantenerumab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

Genentech's Gantenerumab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

  • October 11, 2021
Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

  • June 30, 2021
Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

  • June 25, 2021
Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease

Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease

  • June 24, 2021
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

  • June 17, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.